Search tips
Search criteria 


Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
J Virol. 1996 June; 70(6): 3930–3937.
PMCID: PMC190271

Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.


The dengue type 4 virus (DEN4) genome contains a 384-nucleotide (nt) 3' noncoding sequence in which the last 81 nt, predicted to form a secondary structure, are thought to be essential for virus replication. Immediately upstream of the secondary structure, short RNA sequences that are conserved among mosquito-borne flaviviruses have been identified. A series of deletions that range from 30 to 262 nt were introduced into this upstream region of full-length DEN4 cDNA to create viable deletion mutants, some of which might prove to be useful for inclusion in a live attenuated virus vaccine. When studied by an infectious-center assay, most full-length RNA transcripts of the deletion constructs exhibited reduced infectivity when transfected into simian LLC-MK2 cells compared with the full-length RNA transcripts of wild-type parental virus. Deletion mutations that extended as far as the 5' boundary of the 3' noncoding region and whose 3' boundary did not extend beyond the last 113 nt of the 3' end were viable. With the exception of mutant 3'd 303-183, which contained a deletion of nt 303 to 183 from the 3' terminus, deletion mutants produced plaques that appeared late on simian LLC-MK2 cells or exhibited a small-plaque morphology on mosquito C6/36 cells compared with the wild-type virus. These mutants also replicated less efficiently and attained a lower titer in LLC-MK2 cells than parental wild-type virus. Significantly, mutant 3'd 303-183 grew to a high titer and was least restricted in growth. Mutant 3'd 303-183 and four other moderately to severely restricted mutants were selected for evaluation of infectivity and immunogenicity in rhesus monkeys. There was a suggestion that occurrence and duration of viremia were reduced for some of the deletion mutants compared with the wild-type virus. However, more convincing evidence for attenuation of some of the mutants was provided by an analysis of antibody response to infection. Mutant 3'd 303-183 induced an antibody response equivalent to that stimulated by wild-type virus, whereas other mutants induced low to moderate levels of antibodies, as measured by radioimmunoprecipitation and virus neutralization. The immunogenicity of these 3' DEN4 deletion mutants in monkeys appeared to correlate with their efficiency of growth in simian LLC-MK2 cells. One or more mutants described in this paper may prove to be useful for immunization of humans against disease caused by dengue virus.

Full Text

The Full Text of this article is available as a PDF (640K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • ADA GL, ANDERSON SG. Yield of infective ribonucleic acid from impure Murray Valley encephalitis virus after different treatments. Nature. 1959 Mar 21;183(4664):799–800. [PubMed]
  • Bancroft WH, Scott RM, Eckels KH, Hoke CH, Jr, Simms TE, Jesrani KD, Summers PL, Dubois DR, Tsoulos D, Russell PK. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis. 1984 Jun;149(6):1005–1010. [PubMed]
  • Bartholomeusz AI, Wright PJ. Synthesis of dengue virus RNA in vitro: initiation and the involvement of proteins NS3 and NS5. Arch Virol. 1993;128(1-2):111–121. [PubMed]
  • Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ. 1987;65(2):189–195. [PubMed]
  • Bray M, Men R, Lai CJ. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol. 1996 Jun;70(6):4162–4166. [PMC free article] [PubMed]
  • Brinton MA, Fernandez AV, Dispoto JH. The 3'-nucleotides of flavivirus genomic RNA form a conserved secondary structure. Virology. 1986 Aug;153(1):113–121. [PubMed]
  • Cahour A, Pletnev A, Vazielle-Falcoz M, Rosen L, Lai CJ. Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome. Virology. 1995 Feb 20;207(1):68–76. [PubMed]
  • Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 1990;44:649–688. [PubMed]
  • Eckels KH, Scott RM, Bancroft WH, Brown J, Dubois DR, Summers PL, Russell PK, Halstead SB. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg. 1984 Jul;33(4):684–689. [PubMed]
  • Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL, Hoke CH. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis. 1994 Dec;170(6):1448–1455. [PubMed]
  • Grun JB, Brinton MA. Dissociation of NS5 from cell fractions containing West Nile virus-specific polymerase activity. J Virol. 1987 Nov;61(11):3641–3644. [PMC free article] [PubMed]
  • Hahn CS, Hahn YS, Rice CM, Lee E, Dalgarno L, Strauss EG, Strauss JH. Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences. J Mol Biol. 1987 Nov 5;198(1):33–41. [PubMed]
  • Harrison VR, Eckels KH, Sagartz JW, Russell PK. Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates. Infect Immun. 1977 Oct;18(1):151–156. [PMC free article] [PubMed]
  • Hoke CH, Jr, Malinoski FJ, Eckels KH, Scott RM, Dubois DR, Summers PL, Simms T, Burrous J, Hasty SE, Bancroft WH. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg. 1990 Aug;43(2):219–226. [PubMed]
  • HOTTA S. Experimental studies on dengue. I. Isolation, identification and modification of the virus. J Infect Dis. 1952 Jan-Feb;90(1):1–9. [PubMed]
  • Innis BL, Eckels KH, Kraiselburd E, Dubois DR, Meadors GF, Gubler DJ, Burke DS, Bancroft WH. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis. 1988 Oct;158(4):876–880. [PubMed]
  • Jacobson SJ, Konings DA, Sarnow P. Biochemical and genetic evidence for a pseudoknot structure at the 3' terminus of the poliovirus RNA genome and its role in viral RNA amplification. J Virol. 1993 Jun;67(6):2961–2971. [PMC free article] [PubMed]
  • Kuhn RJ, Griffin DE, Zhang H, Niesters HG, Strauss JH. Attenuation of Sindbis virus neurovirulence by using defined mutations in nontranslated regions of the genome RNA. J Virol. 1992 Dec;66(12):7121–7127. [PMC free article] [PubMed]
  • Kuhn RJ, Hong Z, Strauss JH. Mutagenesis of the 3' nontranslated region of Sindbis virus RNA. J Virol. 1990 Apr;64(4):1465–1476. [PMC free article] [PubMed]
  • Lai CJ, Zhao BT, Hori H, Bray M. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5139–5143. [PubMed]
  • Marchette NJ, Dubois DR, Larsen LK, Summers PL, Kraiselburd EG, Gubler DJ, Eckels KH. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies. Am J Trop Med Hyg. 1990 Aug;43(2):212–218. [PubMed]
  • Morozova OV, Belyavskaya NA, Zaychikov EF, Kvetkova EA, Mustaev AA, Pletnev AG. Identification of RNA replicase subunits responsible for initiation of RNA synthesis of tick-borne encephalitis virus by affinity labelling. Biomed Sci. 1991;2(2):183–186. [PubMed]
  • Pethel M, Falgout B, Lai CJ. Mutational analysis of the octapeptide sequence motif at the NS1-NS2A cleavage junction of dengue type 4 virus. J Virol. 1992 Dec;66(12):7225–7231. [PMC free article] [PubMed]
  • Pletnev AG, Bray M, Huggins J, Lai CJ. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10532–10536. [PubMed]
  • Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science. 1985 Aug 23;229(4715):726–733. [PubMed]
  • ROSEN L. Experimental infection of New World monkeys with dengue and yellow fever viruses. Am J Trop Med Hyg. 1958 Jul;7(4):406–410. [PubMed]
  • SABIN AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952 Jan;1(1):30–50. [PubMed]
  • SABIN AB. Recent advances in our knowledge of dengue and sandfly fever. Am J Trop Med Hyg. 1955 Mar;4(2):198–207. [PubMed]
  • Takegami T, Washizu M, Yasui K. Nucleotide sequence at the 3' end of Japanese encephalitis virus genomic RNA. Virology. 1986 Jul 30;152(2):483–486. [PubMed]
  • Wengler G, Castle E. Analysis of structural properties which possibly are characteristic for the 3'-terminal sequence of the genome RNA of flaviviruses. J Gen Virol. 1986 Jun;67(Pt 6):1183–1188. [PubMed]
  • Zhao B, Mackow E, Buckler-White A, Markoff L, Chanock RM, Lai CJ, Makino Y. Cloning full-length dengue type 4 viral DNA sequences: analysis of genes coding for structural proteins. Virology. 1986 Nov;155(1):77–88. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)